

Phenotypic and transcriptional analysis of the antimicrobial effect of lactic acid bacteria on carbapenem-resistant *Acinetobacter baumannii*: *Lacticaseibacillus rhamnosus* CRL 2244 an alternative strategy to overcome resistance?”

Cecilia Rodriguez

Centro de Referencia para Lactobacilos (CERELA), CONICET

Dema Ramlaoui

Center for Applied Biotechnology Studies, Department of Biological Science, College of Natural Sciences and Mathematics, California State University Fullerton

Nardin Georgeos

Center for Applied Biotechnology Studies, Department of Biological Science, College of Natural Sciences and Mathematics, California State University Fullerton

Briea Gasca

Center for Applied Biotechnology Studies, Department of Biological Science, College of Natural Sciences and Mathematics, California State University Fullerton

Camila Leal

Centro de Referencia para Lactobacilos (CERELA), CONICET

Tomás Subils

Instituto de Procesos Biotecnológicos y Químicos de Rosario (IPROBYQ, CONICET-UNR)

Marisel R Tuttobene

Instituto de Biología Molecular y Celular de Rosario (IBR, CONICET-UNR)

Rodrigo Sieira

Fundación Instituto Leloir - IIBBA CONICET

Nicholas T. Salzameda

Department of Chemistry and Biochemistry, College of Natural Science and Mathematics, California State University Fullerton

Robert A. Bonomo

Research Service and GRECC, Louis Stokes Cleveland Department of Veterans Affairs Medical Center

Raúl Raya

Centro de Referencia para Lactobacilos (CERELA), CONICET

María Soledad Ramirez (✉ msramirez@fullerton.edu)

Article

Keywords: Acinetobacter baumannii, Lactic acid bacteria, probiotics, carbapenem-resistance, transcriptional response, antagonisms

Posted Date: July 21st, 2023

DOI: <https://doi.org/10.21203/rs.3.rs-3151881/v1>

License:   This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Abstract

Carbapenem-resistant *Acinetobacter baumannii* (CRAB) is a recognized nosocomial pathogen with limited antibiotic treatment options. Lactic acid bacteria (LAB) constitute a promising therapeutic alternative. Here we studied the antibacterial properties of a collection of LAB strains using phenotypic and transcriptomic analysis against *A. baumannii* clinical strains.

One strain, *Lactocaseibacillus rhamnosus* CRL 2244, demonstrated a potent inhibitory capacity on *A. baumannii* with a significant killing activity. Scanning electron microscopy images showed changes in the morphology of *A. baumannii* with an increased formation of outer membrane vesicles. Significant changes in the expression levels of a wide variety of genes were also observed. Interestingly, most of the modified genes were involved in a metabolic pathway known to be associated with the survival of *A. baumannii*. The *paa* operon, Hut system, and fatty acid degradation were some of the pathways that were induced. The analysis reveals the impact of *Lcb. rhamnosus* CRL 2244 on *A. baumannii* response, resulting in bacterial stress and subsequent cell death. These findings highlight the antibacterial properties of *Lcb. rhamnosus* CRL 2244 and its potential as an alternative or complementary strategy for treating infections. Further exploration and development of LAB as a treatment option could provide valuable alternatives for combating CRAB infections.

Introduction

Carbapenem-resistant *Acinetobacter baumannii* (CRAB) has gained notoriety in recent years due to its rapid nosocomial emergence and global spread. CRAB causes severe infections in vulnerable patients and is also known to colonize the rectum of patients and workers associated with intensive care units (1–3). The circulating CRAB strains possess extreme antibiotic resistance (XDR) and in some cases pan-drug resistance (PDR) (4), which severely complicates therapy with currently available antibiotics. In the last decade, and despite numerous efforts to find therapeutic alternatives, the production of new drugs for the treatment of infections caused by CRAB has been scarce.

Lactic acid bacteria (LAB) constitute a promising therapeutic alternative due to the demonstrated ability of certain LAB strains to inhibit ESKAPE group pathogens (*Staphylococcus aureus*, *Escherichia coli*, *Klebsiella pneumoniae*, *Acinetobacter baumannii*, *Pseudomonas aeruginosa*, and *Enterococcus faecalis*) (5–9). LAB are Gram-positive microorganisms considered safe for inclusion in food (GRAS) and are widely used in the production of various fermented foods, where they contribute taste and texture of the final product (10, 11). LAB are widely distributed in nature and many of them are found as part of the gut microbiota of humans and animals. Strains of different LAB species are used as probiotic supplements for their beneficial properties for human or animal health. These benefits range from improving intestinal health and immune response (12), to preventing acute and antibiotic-associated diarrhea (13), and chronic gastritis (14, 15), among others. The antimicrobial effect of LAB against pathogens constitutes an important property in the selection of potential probiotics for the maintenance of intestinal microbial balance and as a substitute for synthetic antibiotics (16). Probiotic LAB are antagonistic to pathogens

and inhibit the growth of these bacteria by i) producing antimicrobial substances or bioactive compounds (7–9, 17); ii) by occupying their niches and/or displacing them (including in the prevention and/or elimination of biofilms) (5); iii) by promoting gut maturation and integrity, and increasing the non-immune-dependent barrier effect; or by directly activating lymphoid cells, partly mediated by gut-associated lymphoid tissue (GALT system), and iv) modulating local as well as systemic immune responses (6, 18, 19).

The antimicrobial activity of certain LAB and/or their extracellular products against *A. baumannii* have been described. (20). In a murine model of respiratory infection, demonstrated that *Streptococcus constellatus*, frequently isolated from the oral cavity, enhances the immune response of mice by promoting the proliferation of cytotoxic lymphocytes that eliminate *A. baumannii*. Stanbro et al. (2020) (19) demonstrated that topical application of certain products of *Lcb. acidophilus* ATCC 4356 and *L. reuteri* ATCC 23272 were effective in resolving wounds caused by *A. baumannii*. Furthermore, *in vitro* studies demonstrated the antagonistic activity of different LAB strains such as *L. animalis* LMEM6, *L. plantarum* LMEM7, *L. acidophilus* LMEM8, *Lcb. rhamnosus* LMEM9, *Lcb. casei* Shirota, *L. plantarum* LJ1R3, and *L. gasseri* LBM220 against clinical isolates of *A. baumannii* MDR (5, 8, 21, 22). While there is evidence that LAB exert an antagonistic effect against *A. baumannii*, the specific response of *A. baumannii* and the impact of LAB on its survival, virulence, and persistence have not been thoroughly examined. The aim of this study is to address the knowledge gap regarding the response of *A. baumannii* to the antagonistic effect of LAB and to investigate how the presence of LAB affects the behavior of *A. baumannii* providing insights that can contribute to strategies for the control of nosocomial infections. Herein, we will assess various aspects of *A. baumannii*'s behavior, including its growth rate, biofilm formation, antibiotic susceptibility, and expression of virulence associated genes.

Results

1) Inhibitory effect of ten different LAB on *A. baumannii* clinical strains

We initially evaluated the inhibitory activity of ten different LAB species on the antibiotic-susceptible representative strain *A. baumannii* A118 by agar overlay testing the overnight culture, the collect pellet, and the supernatant of the LABs. In the solid medium bacterial interaction assays, most of the tested strains showed low or absent inhibitory capacity on A118 (Table 1). However, strong inhibition activity defined as "high R value" was observed around the culture and pellet of *Lcb. rhamnosus* CRL 2244 (7 and 7.5, respectively) (Table 1). The antagonistic effect represented as arbitrary units/ml reached 1600 and 1650 for culture and pellet of *Lcb. rhamnosus* CRL 2244, respectively (Table 1) Particularly, the same strong" inhibition halos on A118 were also observed when serial dilutions of an overnight culture of CRL 2244 were seeded on a 10^8 CFU lawn of the indicator model strain A118 (Fig. 1A).

Table 1

Soft agar overlay assay. Antimicrobial activity of culture (C), pellet (P) and supernatant (S) spot of LAB on *A. baumannii* A118 at 16h incubation. Inhibition halos diameter (IHD) were measured, and inhibitory capacity was interpreted > 20 mm = High (H), 20 - 10 mm = Intermediate (I) and < 10 mm = Low (L). The width of the clear zone (R) is the difference between IHD and spot diameter divided by two (SD), inhibitory capacity was interpreted as R > 6 mm = High (H), 5 - 2 mm = Low (L), < 2 mm = Without Inhibition (WI). The arbitrary units per ml (AU/ml) was calculated as the IHD X 1000 divided by the μ l seed (halder et al 2017). The average of three independent assays is represented on the table.

Strains	IHD (mm)	SD (mm)	R	AU/ml
<i>L. curvatus</i> CRL705	C = 16	C = 10	3 L	800
	P = 18	P = 8	5 L	900
	S = 0	S = 0	WI	0
<i>L. mucosae</i> CRL573	C = 16	C = 11	2.5 L	800
	P = 16	P = 9	3.5 L	800
	S = 0	S = 0	WI	0
<i>L. acidophilus</i> CRL641	C = 0	C = 11	WI	0
	P = 15	P = 9	3 L	750
	S = 0	S = 0	WI	0
<i>F. tropealis</i> CRL2034	C = 12	C = 10	WI	600
	P = 12	P = 9	WI	600
	S = 0	S = 0	WI	0
<i>L. reuteri</i> CRL1101	C = 7	C = 6	WI	350
	P = 16	P = 9	3.5 L	800
	S = 0	S = 0	WI	0
<i>C. farciminis</i> CRL748	C = 0	C = 8	WI	0
	P = 15	P = 8	3.5 L	750
	S = 0	S = 8	WI	0
<i>Lcb. rhamnosus</i> ATCC53103	C = 0	C = 8	WI	0
	P = 12	P = 8	WI	600
	S = 0	S = 8	WI	0

Strains	IHD (mm)	SD (mm)	R	AU/ml
<i>Lcb. rhamnosus</i>	C = 15	C = 11	2 L	750
CRL75	P = 15	P = 8	3.5 H	750
	S = 6	S = 6	WI	300
<i>Lcb. rhamnosus</i>	C = 10	C = 8	WI	500
Principia	P = 14	P = 8	3 L	700
	S = 0	S = 8	WI	0
<i>Lcb. rhamnosus</i>	C = 32	C = 9 (18)	7 H	1600
CRL 2244	P = 33	P = 8 (18)	7.5 H	1650
	S = 0	S = 6	WI	0

Therefore, *Lcb. rhamnosus* CRL 2244 was selected to evaluate its antimicrobial activity by agar overlay against CRAB strains from different clonal complexes, harboring different types of carbapenemases and with extreme antibiotic resistance (XDR). In addition, a model probiotic strain commonly used to treat or prevent diarrhea, *Lcb. rhamnosus* ATCC 53103 (GG), was included. CRL 2244, in the assayed conditions, inhibited strains AB5075 (hypervirulent strain), AMA16, AB0057 ABUH702 and AYE, with "strong" inhibition halo diameters (DHI > 20 mm); however, inhibition of strain ABUH702 was weak (DHI < 10 mm) (Fig. 1B). The strain ATCC 53103, in the assayed conditions, did not show antimicrobial activity on any of the CRAB strains evaluated (data not shown).

2) *Lcb. rhamnosus* CRL 2244 possessed a potent killing activity against carbapenem-susceptible and CRAB strains

To evaluate the killing activity of *Lcb. rhamnosus* CRL 2244, we assessed the viability of AB5075 and A118 24 h after co-incubation of cells with CRL 2244. Both cells in ratio 1:1 and in stationary phase (without the addition of fresh medium) were used. Total cell death was observed in both cases with a survival rate less than 1×10^{-9} and less than 1×10^{-8} for AB5075 and A118, respectively.

Then, to determine the time-killing effect during 24 h course of A5075 co-incubated (without addition of fresh medium) and co-cultured (with addition of fresh medium) with *Lcb. rhamnosus* CRL 2244 was assessed. AB5075 cells were combined with *Lcb. rhamnosus* CRL 2244 in a 1:1 ratio of cultures with OD 600nm = 0.1. In the absence of fresh medium, cell death of AB5075 was observed at short cell-cell contact time of 4 h (Fig. 2A). In contrast, when fresh BHI medium was added, CFU decreased was observed after six hours with a total cell death after 24 hours of incubation (Fig. 2B).

3) In co-culture conditions, *Lcb. rhamnosus* CRL 2244 does not induce changes in antibiotic susceptibility

Susceptibility to antibiotics of AB5075 and A118 co-cultured with *Lcb. rhamnosus* CRL 2244 during 4 h with addition on fresh medium was evaluated by the disc diffusion and gradient diffusion. The antibiotic susceptibility profile of A118 and AB5075 strain in the presence of CRL 2244 was similarly to the unexposed strains in the condition tested (data not shown).

4) *Lcb. rhamnosus* CRL 2244 induces morphological changes on *A. baumannii* cell

SEM analysis was performed to study if *A. baumannii* experience changes at the morphological level in the presence of *Lcb. rhamnosus* CRL 2244. Microscopic images show that *A. baumannii* cells in the absence of *Lcb. rhamnosus* CRL 2244 (control) are cocco-bacillary in shape, uniform in size at approximately 600–700 nm in length, have a rugged surface, and are homogeneously distributed and immersed in an extracellular matrix or biofilm (Fig. 3). When *A. baumannii* was exposed to *Lcb. rhamnosus* CRL 2244, changes in bacterial surface, cell size, and distribution were observed. While the surface remains rugged, the formation of nanotubes and outer membrane vesicles (OMVs) significantly increased compared to control cells grown in the absence of *Lcb. rhamnosus* CRL 2244 (Fig. 3). The size of the cells is variable, some preserving their shape while others show increase in length (sizes of approximately 1000 nm) (Fig. 3). In addition, it is observed that *A. baumannii* cells are distributed forming multicellular three-dimensional conglomerates around *Lcb. rhamnosus* CRL 2244 chains. (Fig. 3). Changes in the morphology of *Lcb. rhamnosus* CRL2244 when interacting with A118 were not observed.

5) *Lcb. rhamnosus* CRL 2244 induces changes at the transcriptional level of *A. baumannii* in co-culture condition

To investigate the transcriptional response of *A. baumannii* when exposed to *Lcb. rhamnosus* CRL 2244, RNA-seq analysis and quantitative RT-PCR (qRT-PCR) were performed.

RNA-seq transcriptomic analysis of *A. baumannii* AB5075 exposed to *Lcb. rhamnosus* CRL 2244, revealed 386 differentially expressed genes (DEGs) using an adjusted P-value < 0.05 and a fold-change cutoff of $\log_2 > 1$. These DEGs represent 10.19% of the total genes in the AB5075 reference genome and encompass a wide range of functional categories. Among the DEGs, 223 were up-regulated and 163 were down-regulated. Notably, these DEGs include genes associated with various important functions, such as iron-uptake, antibiotic resistance, metabolism, cell wall synthesis, virulence, transcriptional regulators, efflux pumps, and motility, among others (Table S2).

Particularly, there is an increase in the expression of genes involved in metabolic processes, such as the catabolism of organic compounds, amino acids, fatty acids, and carbohydrates (Table S2, Fig. 4, and S1). Genes known to have an impact on the pathobiology of *A. baumannii* and having a role on virulence, immune evasion, infection, and antibiotic resistance (23), such as the *paa* operon, are differentially expressed in co-culture condition (Fig. 4A and B). PAA catabolism involves the production of succinyl-CoA and acetyl-CoA, which then participate in the tricarboxylic acid (TCA) cycle; there is differential expression of genes encoding different lyase, ligase, transferase and oxido-reductase enzymes associated with these pathways (Table S2 and Fig. 4A and B). In addition, genes of the HUT system (*hutG*, *hutU*, *hutH*) involved

in histidine catabolism using carbon and nitrogen as source were also found to be up-regulated (Fig. 4C and D). This system has been identified as important for *A. baumannii* infection (24). Other genes found to be up-regulated were those involved in acetoin/butanediol catabolism (*acoA*, *acoB*, *acoC*, *acoD*, *acoN*, and *acoR*), benzoate metabolism (*benA*, *benB*, *benC*, *benD*, *benK*, and *benP2*) and genes associated with alcohol metabolism (Fig. 4E and F, Table S2 and Figure S1).

Regarding changes in the expression of genes involved in fatty acid metabolism an increase in the expression of 34 genes was observed in the presence of *Lcb. rhamnosus* CRL 2244. *lipA*, which is essential for the utilization of long-chain fatty acids, colonization and persistence in *A. baumannii* infection, was among the observed DEGs (Table S2 and Figure S1).

Down-regulation was observed in the expression of genes related to secretion systems, biofilm, and iron metabolism (Fig. 5A-C and Table S2). Overnight cultures of AB5075, *Lcb. rhamnosus* CRL 2244 and AB5075 combined with *Lcb. rhamnosus* CRL 2244 for 24 h were used to assess biofilm formation. A statistically significant decrease in the biofilm production was observed when AB5075 was co-cultured with *Lcb. rhamnosus* CRL 2244 (Figure S2). Selected genes were evaluated by RT-qPCR assays, which revealed no statistically significant changes or displayed results that were both in agreement or disagreement with RNA-seq Data (Figure S3). Lastly, genes encoding LrgB and CidA/LgrA family were found to be significantly over-expressed (Table S2). These proteins affect membrane proton motive force and induce programmed cell death in bacteria (25). In addition, these genes have been identified to be involved in pyruvate uptake system in *Streptococcus mutans* and its role in the connection between cell death and key metabolic pathways (26).

5) Inhibitory effect of *Lcb. rhamnosus* CRL 2244 on a CRAB strain in an environment with other commensal bacteria

The antagonistic activity of *Lcb. rhamnosus* CRL 2244 on AB5075 was evaluated in a complex medium of microorganisms, such human fecal material. For this purpose, commercially obtained human fecal material from a healthy donor was used. *Lcb. rhamnosus* CRL 2244 also affected the viability of AB5075 in the presence of a commensal microbiota. A 35% decrease in AB5075 viability was observed in co-culture with *Lcb. rhamnosus* CRL 2244 relative to control AB5075 (1.3×10^8 vs 2.0×10^8 CFU/mL). However, no changes in the phenotypes of surviving AB5075 cells (motility and antibiotic susceptibility profile) were observed. Furthermore, *Lcb. rhamnosus* CRL 2244 reduced the total microbial load of the human fecal material by up to 50% (2.0×10^8 vs 4.0×10^8 CFU/mL human fecal control) and was able to inhibit the *Escherichia coli* population present in the human fecal sample (data not shown).

Discussion

LAB have a long history of safe use in food, where they impart desired technological and nutritional properties to fermented products. In addition, certain species exert beneficial effects on the health of the host. The antagonistic or antimicrobial effect of LAB against pathogens has been well documented in the

literature (5, 9). However, studies on the antimicrobial activity of LAB and/or its extracellular products against *A. baumannii* are currently limited (7, 9, 27). In the present work we observed a strong inhibitory activity of the LAB *Lcb. rhamnosus* CRL 2244 on susceptible and carbapenem-resistant *A. baumannii* strains. *Lcb. rhamnosus* CRL 2244 exerts a killing effect in *A. baumannii* cells in both exponential and stationary phase. In addition, the morphology of *A. baumannii* cells displayed alterations when exposed to *Lcb. rhamnosus* CRL 2244. These changes included variations in size, distribution, and the quantity of OMVs released by *A. baumannii*, indicating a potential defensive response, and suggesting that *A. baumannii* cells may be experiencing stress. Ladha et al. (7), have shown that a pure compound produced by *Lactiplantibacillus plantarum* LJR13 produced pores on the surface of *Listeria monocytogenes*, *S. aureus*, and *A. baumannii* affecting the bacterial surface (7). Previous studies have demonstrated that exposure of *A. baumannii* cells to lactic acid and acetic acid produced by *Lcb. rhamnosus* can lead to the disruption or disintegration of the *A. baumannii* cell envelope. Additionally, these authors observed the emergence of filament-like structures, which can serve as sites for the excessive leakage of vital cytoplasmic contents (27).

Through our transcriptomic analysis of *A. baumannii* cell co-culture with *Lcb. rhamnosus* CRL 2244, we observed that the expression of various genes is significantly altered. Interestingly, the majority of differentially expressed genes (DEGs) are associated with metabolic pathways, indicating that *A. baumannii* is actively responding to the stress imposed by the LAB to enhance its survival strategies. The organic acid phenylacetate (PAA) catabolic pathway, which plays a crucial role in various biological processes, is among the metabolic pathways that have been found to be altered. The catabolism of PAA has been associated with immune evasion, colonization, persistence, biofilm formation, oxidative stress, and antibiotic resistance (28–31). Interestingly, the expression of genes within the *paa* operon is influenced by different environmental conditions, including exposure to human pleural fluid, mucin, and antibiotics, highlighting how *A. baumannii* employs diverse strategies to overcome environmental stress. The increase expression of the *paa* operon has been linked with the repression of the CSU pili, leading to decrease biofilm formation (28). Our RNA-seq data and biofilm formation assays agree with this study. In our study, we observed the up-regulation of the *hut* system, which is recognized for enabling the utilization of histidine during infection. This finding further reinforces the metabolic adaptability of *A. baumannii*, which is crucial for its survival within the host environment. The metabolism of fatty acids is strongly increase in the presence of the LAB bacteria. Previous reports have shown that host fatty acid have an antimicrobial property during infection (32–34). Other authors showed that *A. baumannii* β -oxidation may metabolize the toxic fatty acids allowing *A. baumannii* to resist during infection (32–34). It has also been reported that this species can use fatty acids as energy sources or substrate for membrane biosynthesis (35). Rodman et al. (36) observed that when *A. baumannii* is exposed to human pleural fluid or human proteins, such as HSA, there is an increase in the expression of genes associated with fatty acids metabolism (36). The comprehensive analysis of the transcriptomic data highlights that in the presence of *Lcb. rhamnosus* CRL 2244, *A. baumannii* exhibits a remarkable and versatile metabolic adaptability as a direct response to the stress imposed by the LAB. This adaptability indicates that *A. baumannii* possesses the capability to dynamically adjust its metabolic pathways to respond to the

challenges presented by the presence of *Lcb. rhamnosus* CRL 2244. Such adaptability is likely crucial for *A. baumannii*'s survival and persistence in the face of environmental stressors.

Another notable finding in the transcriptional response of *A. baumannii* is the significant over-expression of the *cidA* and *lrgB* genes. These genes have been implicated in programmed cell death and have been previously associated with cellular responses during overflow metabolism (37). Based on our data, we suggest that the presence of *Lcb. rhamnosus* CRL 2244 can induce stress and potential cellular death in *A. baumannii*, likely due to the heightened metabolic activity observed under these conditions. This observation aligns with the documented phenomenon of *A. baumannii* experiencing cell death after 24 hours in the presence of *Lcb. rhamnosus* CRL 2244.

The results presented in this study support the notion that *Lcb. rhamnosus* CRL 2244 could be used as an adjunct therapy to complement existing treatments for *A. baumannii* infections. Furthermore, the observed ability of the LAB to induce a broad transcriptomic response in *A. baumannii* highlights the complex interactions between these organisms. This work provides a foundation for future investigations aimed at elucidating the underlying mechanisms involved and developing novel therapeutic strategies for combating *A. baumannii* infections.

Materials and Methods

Bacterial strains and culture conditions

Ten lactic acid bacteria (LAB) strains were used to evaluate their antimicrobial activity against *A. baumannii*. The strains included were the model probiotic strain *Lacticaseibacillus rhamnosus* ATCC 53103; and strains with technological and/or functional properties of interest (38–43), belonging to the CERELA culture collection (CRL) or to the laboratory's collection as *Latilactobacillus curvatus* CRL705, *Limosilactobacillus mucosae* CRL573, *Lactobacillus acidophilus* CRL641, *Fructobacillus tropaeolis* CRL2034, *Limosilactobacillus reuteri* CRL1101, *Companilactobacillus farciminis* CRL748, *Lacticaseibacillus rhamnosus* CRL75, CRL 2244 and Principia (Table S1). The strains were subcultured at the optimum temperature for each one twice in Man, Rogosa and Sharpe (MRS) broth (Oxoid, Basingstoke, Hampshire, United Kingdom) before experimental use.

Two *A. baumannii* model strains, the A118 antibiotic-susceptible strain (44) and the CRAB AB5075 (*bla*_{OXA-23} and *bla*_{OXA-51}, (45)), were used in this work. Also, four additional CRAB clinical strains belonging to different clonal complexes and harboring different types of carbapenemases as AMA16 (*bla*_{NDM-1} and *bla*_{PER-7}, (46)), AB0057 (*bla*_{TEM-1}, *bla*_{OXA-23}, *bla*_{ADC}, (47)), ABUH702 (*ISAb*₁/OXA-66 (48), and AYE (VEB-1, OXA-69 (49) were tested. The strains were grown at 37°C in BHI broth (Oxoid, Basingstoke, Hampshire, United Kingdom) with agitation.

Antagonistic or inhibitory activity of lactic acid bacteria on *A. baumannii* strains

The antagonistic or inhibitory activity of LAB against the different *A. baumannii* indicator strains was determined by soft agar overlay method (5). Briefly, spots (10^5 CFU/spot) of culture (C), supernatant (S) and pellet (P) (S and P obtained by centrifuging the culture at 10,000 rpm for 5 min) of different LAB were inoculated onto MRS agar plates, using a culture in MRS broth (grown at 37° or 30°C for 24 h), and allowed to dry for 30 min. They were then covered with Muller-Hinton (MH) soft agar (0.8% agar) premixed with 10^8 CFU of *A. baumannii* indicator strains and incubated at 37°C for 24 h. The diameter of the *A. baumannii* growth inhibition halo (IHD) was measured and interpreted according to Shokryazdan et al (2014) (50): the IHD > 20 mm (Strong); 20 – 10 mm (intermediate); and < 10 mm (weak). The width of the clear zone or "R" value was also determined according to the formula $R = \text{Inhibition diameter} - \text{Spot diameter} / 2$ (5); and will be interpreted "no inhibition capacity" when $R < 2$ mm, "low inhibition" with "R" values of 2–5 mm, and "high inhibition capacity" with "R" values > 6 mm (51, 52). AU/ml (arbitrary units per ml) was calculated as the IHD X 1000 divided by the μl seed (5). The assays were performed in triplicate.

Killing assay

The viability of *A. baumannii* AB5075 and A118 in co-culture with *Lcb. rhamnosus* CRL 2244 was assessed by a) combining ON cultures of both cells (1:1 ratio of cultures with OD 600nm = 0.1) with no addition of fresh medium and b) combining 1:1 ratio of cultures with OD 600nm with addition of fresh BHI medium, incubated at 37°C for 24 h. *A. baumannii* and CRL 2244 independent cultures were used as controls. CFU/mL were determined at different incubation times by decimal dilutions and plated on CLDE medium (Sigma-Aldrich, St. Louis, MO, USA) with and without the addition of erythromycin (2 $\mu\text{g}/\text{mL}$) to kill *Lcb. rhamnosus* CRL 2244.

Antibiotic susceptibility assays

Susceptibility to antibiotics of AB5075 co-cultured with CRL 2244 during 4 h was evaluated by the disc diffusion and gradient diffusion (minimum inhibitory concentration) following the procedures recommended by the Clinical and Laboratory Standards Institute (53). Commercial antimicrobial discs (Liofilchem S.r.l., Italy) of 30 μg of cefepime (FEP), 30 μg of ceftazidime (CAZ), 10 μg of imipenem (IMP), 10 μg of meropenem (MER), 30 μg cefiderocol (FDC), amikacin (AK), 5 μg of ciprofloxacin (CIP) were used and the plates were incubated at 37°C for 18 h. MICs to cefiderocol (FDC) and tetracycline (TE) were performed by MTS (Liofilchem S.r.l., Italy) following manufacturer's recommendations. Assays were performed in triplicate.

Scanning electronic microscopy

From overnight cultures of A118 in BHI broth (incubated at 37°C with shaking) and CRL2244 in MRS broth (incubated at 37°C), 500 μl of each were combined (co-culture) and incubated at 37°C without shaking for 1h 30 min. Controls included individual cultures of both cells. The samples were then centrifuged at 500 rpm for 2 min. To the collected pellet, 1 mL of Karnovsky fixative pH 7.2 (2.66%

paraformaldehyde, 0.1 M sodium phosphate buffer and 1.66% glutaraldehyde) was added and homogenized. Then, 100 μ L were placed on the surface of a 10 mm diameter glass coverslip, allowed to dry for one hour and dehydrated using a battery of alcohol solutions of increasing gradation 30°, 50°, 70°, 90°, 100° and acetone for 10 min each. After acetone, critical point drying was performed in Denton vacuum equipment model DCP-1. The glasses were mounted on an aluminum support (stub) and adhered by means of a double-sided conductive carbon tape. They were then coated with gold in a JEOL model JFC-1100 ion sputter. The electron microscopic observation was performed with the ZeissSupra 55VP Scanning Electron Microscope (Germany) belonging to the Centro Integral de Microscopia Electronica (CIME-CONICET- Universidad Nacional de Tucumán).

RNA extraction sequencing and RNA-seq data analysis

Overnight cultures of *A. baumannii* AB5075 and CRL 2244 with OD adjusted to 600 nm at 4.0 were centrifuged and resuspended in 3 mL of BHI broth and incubated for 90 min at 37°C. Total RNA extractions were performed in three biological replicates for each condition (AB5075 combined with CRL 2244 and AB5075) using Direct-zol RNA Kit (Zymo Research). After checking the absence of DNA contamination, Novogene Corporation (CA) was outsourced to perform mRNA-seq analysis, which included rRNA depletion, library preparation following the protocols of the NEBNext Ultra II Directional RNA Library Prep Kit for Illumina (New England Biolabs) and Illumina NovaSeq 6000 paired-end 150 bp sequencing. The RNA-seq reads (GEO accession GSE236782) corresponding to *A. baumannii* AB5075 exposed to CRL 2244 were analyzed as follows. First, Trimmomatic v0.39 was used to trim low-quality bases at the ends of the reads to a minimum length of 100 bp and remove Illumina adaptor sequences. Then, FastQC (www.bioinformatics.babraham.ac.uk/projects/fastqc/) was used to assess the quality of the reads before and after trimming. The RNA-seq reads were aligned to whole genome sequence of AB5075 using Burrows-Wheeler Alignment software (BWA). FeatureCounts was used to calculate the read counts per gene, and DESeq2 was employed to perform differential expression analysis. Features exhibiting FDR < 0.05 and log₂fold change > 1 were considered statistically significant.

Quantitative Reverse Transcription Polymerase Chain Reaction (qRT-PCR)

The extracted and DNase-treated RNA was utilized to generate complementary DNA (cDNA) following the manufacturer's protocol provided with the iScript™ Reverse Transcription Supermix for qPCR (Bio-Rad, Hercules, CA, USA). cDNA concentrations were adjusted to 50 ng/ μ L and qPCR was conducted using the qPCRBIO SyGreen Blue Mix Lo-ROX following manufacturer's protocol (PCR Biosystems, Wayne, PA, USA). At least three biological replicates of cDNA were used in triplets and were run using the CFX96 Touch™ Real-Time PCR Detection System (Bio-Rad, Hercules, CA, USA). Transcriptional levels of each sample were normalized to the transcriptional level of *rpoB*. The relative quantification of gene expression was performed using the comparative threshold method $2^{-\Delta\Delta C_t}$. The ratios obtained after normalization were expressed as fold changes compared to cDNA samples isolated from bacteria cultures individually, and asterisks were used to indicate statistically significant differences, as determined by ANOVA followed by

Tukey's multiple comparison test ($P < 0.05$), using GraphPad Prism (GraphPad Software, San Diego, CA, USA).

Biofilm formation assay

Overnight cultures of AB5075, CRL 2244, and AB5075 combined with CRL 2244 were incubated in BHI at 37°C for 24 h. The optical density at 600 nm (OD_{600}) was adjusted to 0.9–1.1 and 100 μ l placed in a 96-well polystyrene microtiter plate and incubated at 37°C for 24 h without shaking. The next day, the OD_{600} (ODG) was measured, using a microplate reader, to determine the total biomass. The wells were emptied, washed three times with 1X phosphate buffered saline (PBS) and stained with 1% crystal violet (CV) for 15 min. Excess CV was removed by washing three more times with 1X PBS and the biofilm associated with CV was solubilized in ethanol acetate (80:20) for 30 min. OD_{580} (ODB) was measured and the ratio of biofilm to total biomass (ODB/ODG) was determined. Experiments were performed in triplicate and statistical significance ($P < 0.05$) was determined by two-way ANOVA followed by Tukey's multiple comparison test using GraphPad Prism (GraphPad software, San Diego, CA, USA).

Human fecal material and interaction assays

A stock solution of commercially obtained healthy donor human fecal material (Innovative Research, USA, certified vendor approved by ISO, FDA, USDA, and EPA) was prepared by dissolving 5 g in 50 mL of sterile ultrapure water. From active cultures of CRL 2244 grown in MRS broth and AB5075 in BHI broth and adjusted to $OD_{600} = 0.1$, two hundred μ l of each cell was combined with the addition of 900 μ l of fecal matter and 900 μ l of BHI broth (final volume 2 mL). AB5075 cells were used as controls. After incubation at 37°C for 24 h, the viability of AB5075 and changes in phenotyping were determined:

- a) Cell viability (CFU/mL): using differential media such as CLDE (with and without the addition of erythromycin 2 μ g/mL), Levin; and selective media such as CHROMagar™ Acinetobacter (Chromoagar, Paris, France).
- b) Motility assay in soft agar (0.5% agarose): LB plates were prepared with 0.5% agarose were used. From the colonies obtained in the cell viability assay, colonies were picked and seeded on the surface of the motility plate and incubated at 37°C for 24 h. Growth diameter was measured and classified as non-motile (< 5 mm), moderately motile (5–20 mm) or highly motile (> 20 mm). Experiments were performed in triplicate.
- c) Antibiotic susceptibility assays: From the colonies obtained in the cell viability test, susceptibility was evaluated to cefepime (FEP), ceftazidime (CAZ), imipenem (IMP), meropenem (MER), cefiderocol (FDC), amikacin (AK), gentamicin (GN), ciprofloxacin (CIP), trimethoprim/sulfamethoxazole (TMS) and tetracycline (TE) using the disc diffusion technique and determination of cefiderocol (FDC) and tetracycline (TE) minimum inhibitory concentration, following the procedures recommended by CLSI (2020).

Declarations

Data availability

The datasets generated and analyzed during the current study are available in the Gene Expression Omnibus (GEO) repository, (GEO accession No GSE236782 or token number glcdkswudzkvzuv).

Author Contributions: C.R, D.R, N.G., B.G., N.T.S., R.R, and M.S.R. conceived the study and designed the experiments. C.R, D.R, N.G., B.G., C.L., T.S., M.R.T, R.S., N.T.S., R.R, and M.S.R performed the experiments and genomics and bioinformatics analyses. M.R.T., T.S., R.S., N.T.S, C.R, R.A.B, R.R., and M.S.R. analyzed the data and interpreted the results. C.R., N.T.S., and M.S.R. contributed reagents/materials/analysis tools. C.R., R.S., N.T.S., R.A.B, R.R. and M.S.R. wrote and revised the manuscript. All authors read and approved the final manuscript.

Acknowledgements: The authors' work was supported by NIH SC3GM125556 to MSR, R01AI100560, R01AI063517, R01AI072219 to RAB; PICT2018-03233 to RR and PIP 2020-817 and PICT 2021-00458 to CR. This study was supported in part by funds and/or facilities provided by the Cleveland Department of Veterans Affairs, Award Number 1I01BX001974 to RAB from the Biomedical Laboratory Research & Development Service of the VA Office of Research and Development and the Geriatric Research Education and Clinical Center VISN 10 to RAB. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or the Department of Veterans Affairs. MRT and TS are recipient of a postdoctoral fellowship from CONICET.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Al-Hashem, G., Rotimi, V. O., and Albert, M. J. (2021) Antimicrobial Resistance of Serial Isolates of *Acinetobacter baumannii* Colonizing the Rectum of Adult Intensive Care Unit Patients in a Teaching Hospital in Kuwait. *Microb. Drug Resist.* 27, 64–72
2. Duong, B. T., Duong, M. C., Campbell, J., Nguyen, V. M. H., Nguyen, H. H., Bui, T. B. H., Nguyen, V. V. C., and McLaws, M.-L. (2021) Antibiotic-Resistant Gram-negative Bacteria Carriage in Healthcare Workers Working in an Intensive Care Unit. *Infect. Chemother.* 53, 546
3. Meschiari, M., Kaleci, S., Orlando, G., Selmi, S., Santoro, A., Bacca, E., Menozzi, M., Franceschini, E., Puzzolante, C., Bedini, A., Sarti, M., Venturelli, C., Vecchi, E., and Mussini, C. (2021) Risk factors for nosocomial rectal colonization with carbapenem-resistant *Acinetobacter baumannii* in hospital: a matched case–control study. *Antimicrob. Resist. Infect. Control.* 10, 69
4. Ramirez, M. S., Bonomo, R. A., and Tolmasky, M. E. (2020) Carbapenemases: Transforming *Acinetobacter baumannii* into a Yet More Dangerous Menace. *Biomolecules.* 10, 720
5. Halder, D., Mandal, M., Chatterjee, S., Pal, N., and Mandal, S. (2017) Indigenous Probiotic *Lactobacillus* Isolates Presenting Antibiotic like Activity against Human Pathogenic Bacteria. *Biomedicines.* 5, 31

6. Cazorla, S. I., Maldonado-Galdeano, C., Weill, R., De Paula, J., and Perdigón, G. D. V. (2018) Oral Administration of Probiotics Increases Paneth Cells and Intestinal Antimicrobial Activity. *Front. Microbiol.* 10.3389/fmicb.2018.00736
7. Ladha, G., and Jeevaratnam, K. (2020) A novel antibacterial compound produced by *Lactobacillus plantarum* LJR13 isolated from rumen liquor of goat effectively controls multi-drug resistant human pathogens. *Microbiol. Res.* 241, 126563
8. Rastogi, S., Mittal, V., and Singh, A. (2021) Selection of Potential Probiotic Bacteria from Exclusively Breastfed Infant Faeces with Antagonistic Activity Against Multidrug-Resistant ESKAPE Pathogens. *Probiotics Antimicrob. Proteins.* 13, 739–750
9. Yap, P-C., Ayuhan, N., Woon, J. J., Teh, C. S. J., Lee, V. S., Azman, A. S., AbuBakar, S., and Lee, H. Y. (2021) Profiling of Potential Antibacterial Compounds of Lactic Acid Bacteria against Extremely Drug Resistant (XDR) *Acinetobacter baumannii*. *Molecules.* 26, 1727
10. Tian, H., Shi, Y., Zhang, Y., Yu, H., Mu, H., and Chen, C. (2019) Screening of aroma-producing lactic acid bacteria and their application in improving the aromatic profile of yogurt. *J. Food Biochem.* 10.1111/jfbc.12837
11. Wilkinson, M. G., and LaPointe, G. (2020) Invited review: Starter lactic acid bacteria survival in cheese: New perspectives on cheese microbiology. *J. Dairy Sci.* 103, 10963–10985
12. Maldonado Galdeano, C., Cazorla, S. I., Lemme Dumit, J. M., Vélez, E., and Perdigón, G. (2019) Beneficial Effects of Probiotic Consumption on the Immune System. *Ann. Nutr. Metab.* 74, 115–124
13. Mantegazza, C., Molinari, P., D’Auria, E., Sonnino, M., Morelli, L., and Zuccotti, G. V. (2018) Probiotics and antibiotic-associated diarrhea in children: A review and new evidence on *Lactobacillus rhamnosus* GG during and after antibiotic treatment. *Pharmacol. Res.* 128, 63–72
14. Rodríguez, C. (2010) Therapeutic effect of *Streptococcus thermophilus* CRL 1190-fermented milk on chronic gastritis. *World J. Gastroenterol.* 16, 1622
15. Rodríguez, C., Medici, M., Rodríguez, A. V., Mozzi, F., and Font de Valdez, G. (2009) Prevention of chronic gastritis by fermented milks made with exopolysaccharide-producing *Streptococcus thermophilus* strains. *J. Dairy Sci.* 92, 2423–2434
16. Vinderola, G., Ouwehand, A. C., Salminen, S., and Wright, A. von (eds.) (2019) *Lactic Acid Bacteria*, CRC Press, 10.1201/9780429057465
17. Millette, M., Cornut, G., Dupont, C., Shareck, F., Archambault, D., and Lacroix, M. (2008) Capacity of Human Nisin- and Pediocin-Producing Lactic Acid Bacteria To Reduce Intestinal Colonization by Vancomycin-Resistant Enterococci. *Appl. Environ. Microbiol.* 74, 1997–2003
18. Souza, R. F. S., Rault, L., Seyffert, N., Azevedo, V., Le Loir, Y., and Even, S. (2018) *Lactobacillus casei* BL23 modulates the innate immune response in *Staphylococcus aureus* -stimulated bovine mammary epithelial cells. *Benef. Microbes.* 9, 985–995
19. Stanbro, J., Park, J. M., Bond, M., Stockelman, M. G., Simons, M. P., and Watters, C. (2020) Topical Delivery of *Lactobacillus* Culture Supernatant Increases Survival and Wound Resolution in Traumatic *Acinetobacter baumannii* Infections. *Probiotics Antimicrob. Proteins.* 12, 809–818

20. Alyousef, A. A., and Al-Kadmy, I. M. S. (2017) The effect of immune modulation of *Streptococcus constellatus* SC10 strain upon *Acinetobacter baumannii* infection. *Microb. Pathog.* 111, 370–374
21. Tiengrim, S., and Thamlikitkul, V. (2012) Inhibitory activity of fermented milk with *Lactobacillus casei* strain Shirota against common multidrug-resistant bacteria causing hospital-acquired infections. *J. Med. Assoc. Thai.* 95 Suppl 2, S1-5
22. Sambanthamoorthy, K., Feng, X., Patel, R., Patel, S., and Parnavitana, C. (2014) Antimicrobial and antibiofilm potential of biosurfactants isolated from lactobacilli against multi-drug-resistant pathogens. *BMC Microbiol.* 14, 197
23. Quinn, B., Rodman, N., Jara, E., Fernandez, J. S., Martinez, J., Traglia, G. M., Montaña, S., Cantera, V., Place, K., Bonomo, R. A., Iriarte, A., and Ramírez, M. S. (2018) Human serum albumin alters specific genes that can play a role in survival and persistence in *Acinetobacter baumannii*. 10.1038/s41598-018-33072-z
24. Lonergan, Z. R., Palmer, L. D., and Skaar, E. P. (2020) Histidine Utilization Is a Critical Determinant of *Acinetobacter* Pathogenesis. *Infect. Immun.* 10.1128/IAI.00118 – 20
25. Endres, J. L., Chaudhari, S. S., Zhang, X., Prahlad, J., Wang, S.-Q., Foley, L. A., Luca, S., Bose, J. L., Thomas, V. C., and Bayles, K. W. (2022) The *Staphylococcus aureus* CidA and LrgA Proteins Are Functional Holins Involved in the Transport of By-Products of Carbohydrate Metabolism. *MBio.* 10.1128/mbio.02827-21
26. Ahn, S.-J., Deep, K., Turner, M. E., Ishkov, I., Waters, A., Hagen, S. J., and Rice, K. C. (2019) Characterization of LrgAB as a stationary phase-specific pyruvate uptake system in *Streptococcus mutans*. *BMC Microbiol.* 19, 223
27. Al-Shamiri, M. M., Wang, J., Zhang, S., Li, P., Odhiambo, W. O., Chen, Y., Han, B., Yang, E., Xun, M., Han, L., and Han, S. (2023) Probiotic *Lactobacillus* Species and Their Biosurfactants Eliminate *Acinetobacter baumannii* Biofilm in Various Manners. *Microbiol. Spectr.* 10.1128/spectrum.04614-22
28. Hooppaw, A. J., McGuffey, J. C., Di Venanzio, G., Ortiz-Marquez, J. C., Weber, B. S., Lightly, T. J., van Opijnen, T., Scott, N. E., Cardona, S. T., and Feldman, M. F. (2022) The Phenylacetic Acid Catabolic Pathway Regulates Antibiotic and Oxidative Stress Responses in *Acinetobacter*. *MBio.* 10.1128/mbio.01863-21
29. Bhuiyan, M. S., Ellett, F., Murray, G. L., Kostoulias, X., Cerqueira, G. M., Schulze, K. E., Maifiah, M. H. M., Li, J., Creek, D. J., Lieschke, G. J., and Peleg, A. Y. (2016) *Acinetobacter baumannii* phenylacetic acid metabolism influences infection outcome through a direct effect on neutrophil chemotaxis. *Proc. Natl. Acad. Sci. U. S. A.* 113, 9599–9604
30. Cerqueira, G. M., Kostoulias, X., Khoo, C., Aibinu, I., Qu, Y., Traven, A., and Peleg, A. Y. (2014) A global virulence regulator in *acinetobacter baumannii* and its control of the phenylacetic acid catabolic pathway. *J. Infect. Dis.* 210, 46–55
31. Law, R. J., Hamlin, J. N. R., Sivro, A., McCorrister, S. J., Cardama, G. A., and Cardona, S. T. (2008) A functional phenylacetic acid catabolic pathway is required for full pathogenicity of *Burkholderia cenocepacia* in the *Caenorhabditis elegans* host model. *J. Bacteriol.* 190, 7209–7218

32. Walsh, C. E., Waite, B. M., Thomas, M. J., and DeChatelet, L. R. (1981) Release and metabolism of arachidonic acid in human neutrophils. *J. Biol. Chem.* 256, 7228–7234
33. Rouzer, C. A., Ivanova, P. T., Byrne, M. O., Milne, S. B., Marnett, L. J., and Brown, H. A. (2006) Lipid Profiling Reveals Arachidonate Deficiency in RAW264.7 Cells: Structural and Functional Implications. *Biochemistry.* 45, 14795–14808
34. Bravo, E., Napolitano, M., Benedetti Valentini, S., and Quattrucci, S. (2010) Neutrophil unsaturated fatty acid release by GM-CSF is impaired in cystic fibrosis. *Lipids Health Dis.* 9, 129
35. Zang, M., Ascari, A., Adams, F. G., Alquethamy, S., and Eijkelkamp, B. A. (2023) Characterizing the role of phosphatidylglycerol-phosphate phosphatases in *Acinetobacter baumannii* cell envelope biogenesis and antibiotic resistance. *Cell Surf.* 9, 100092
36. Rodman, N., Martinez, J., Fung, S., Nakanouchi, J., Myers, A. L., Harris, C. M., Dang, E., Fernandez, J. S., Liu, C., Mendoza, A. M., Jimenez, V., Nikolaidis, N., Brennan, C. A., Bonomo, R. A., Sieira, R., and Ramirez, M. S. (2019) Human Pleural Fluid Elicits Pyruvate and Phenylalanine Metabolism in *Acinetobacter baumannii* to Enhance Cytotoxicity and Immune Evasion. *Front. Microbiol.* 10.3389/fmicb.2019.01581
37. Chaudhari, S. S., Thomas, V. C., Sadykov, M. R., Bose, J. L., Ahn, D. J., Zimmerman, M. C., and Bayles, K. W. (2016) The LysR-type transcriptional regulator, CidR, regulates stationary phase cell death in *Staphylococcus aureus*. *Mol. Microbiol.* 101, 942–953
38. Vignolo, G., Fadda, S., de Kairuz, M. N., de Ruiz Holgado, A. A. P., and Oliver, G. (1996) Control of *Listeria monocytogenes* in ground beef by 'Lactocin 705', a bacteriocin produced by *Lactobacillus casei* CRL 705. *Int. J. Food Microbiol.* 29, 397–402
39. LeBlanc, J. G., Garro, M. S., Giori, G. S., and Valdez, G. F. (2004) A Novel Functional Soy-based Food Fermented by Lactic Acid Bacteria: Effect of Heat Treatment. *J. Food Sci.* 69, M246–M250
40. Rodríguez, C., Rimaux, T., Fornaguera, M. J., Vrancken, G., de Valdez, G. F., De Vuyst, L., and Mozzi, F. (2012) Mannitol production by heterofermentative *Lactobacillus reuteri* CRL 1101 and *Lactobacillus fermentum* CRL 573 in free and controlled pH batch fermentations. *Appl. Microbiol. Biotechnol.* 93, 2519–2527
41. Juárez, G. E., Villena, J., Salva, S., de Valdez, G. F., and Rodríguez, A. V. (2013) *Lactobacillus reuteri* CRL1101 beneficially modulate lipopolysaccharide-mediated inflammatory response in a mouse model of endotoxic shock. *J. Funct. Foods.* 5, 1761–1773
42. Ruiz Rodríguez, L. G., Aller, K., Bru, E., De Vuyst, L., Hébert, E. M., and Mozzi, F. (2017) Enhanced mannitol biosynthesis by the fruit origin strain *Fructobacillus tropaeoli* CRL 2034. *Appl. Microbiol. Biotechnol.* 101, 6165–6177
43. Segli, F., Melian, C., Vignolo, G., and Castellano, P. (2021) Inhibition of a spoilage exopolysaccharide producer by bioprotective extracts from *Lactobacillus acidophilus* CRL641 and *Lactobacillus curvatus* CRL705 in vacuum-packaged refrigerated meat discs. *Meat Sci.* 178, 108509
44. Ramirez, M. S., Adams, M. D., Bonomo, R. A., Centrón, D., and Tolmasky, M. E. (2011) Genomic Analysis of *Acinetobacter baumannii* A118 by Comparison of Optical Maps: Identification of

- Structures Related to Its Susceptibility Phenotype. *Antimicrob. Agents Chemother.* 55, 1520–1526
45. Jacobs, A. C., Thompson, M. G., Black, C. C., Kessler, J. L., Clark, L. P., McQueary, C. N., Gancz, H. Y., Corey, B. W., Moon, J. K., Si, Y., Owen, M. T., Hallock, J. D., Kwak, Y. I., Summers, A., Li, C. Z., Rasko, D. A., Penwell, W. F., Honnold, C. L., Wise, M. C., Waterman, P. E., Lesho, E. P., Stewart, R. L., Actis, L. A., Palys, T. J., Craft, D. W., and Zurawski, D. V. (2014) AB5075, a Highly Virulent Isolate of *Acinetobacter baumannii*, as a Model Strain for the Evaluation of Pathogenesis and Antimicrobial Treatments. *MBio.* 10.1128/mBio.01076-14
 46. Adams, M. D., Pasteran, F., Traglia, G. M., Martinez, J., Huang, F., Liu, C., Fernandez, J. S., Lopez, C., Gonzalez, L. J., Albornoz, E., Corso, A., Vila, A. J., Bonomo, R. A., and Ramirez, M. S. (2020) Distinct Mechanisms of Dissemination of NDM-1 Metallo- β -Lactamase in *Acinetobacter* Species in Argentina. *Antimicrob. Agents Chemother.* 10.1128/AAC.00324 – 20
 47. Hujer, K. M., Hujer, A. M., Hulten, E. A., Bajaksouzian, S., Adams, J. M., Donskey, C. J., Ecker, D. J., Massire, C., Eshoo, M. W., Sampath, R., Thomson, J. M., Rather, P. N., Craft, D. W., Fishbain, J. T., Ewell, A. J., Jacobs, M. R., Paterson, D. L., and Bonomo, R. A. (2006) Analysis of Antibiotic Resistance Genes in Multidrug-Resistant *Acinetobacter* sp. Isolates from Military and Civilian Patients Treated at the Walter Reed Army Medical Center. *Antimicrob. Agents Chemother.* 50, 4114–4123
 48. Rodgers, D., Pasteran, F., Calderon, M., Jaber, S., Traglia, G. M., Albornoz, E., Corso, A., Vila, A. J., Bonomo, R. A., Adams, M. D., and Ramírez, M. S. (2020) Characterisation of ST25 NDM-1-producing *Acinetobacter* spp. strains leading the increase in NDM-1 emergence in Argentina. *J. Glob. Antimicrob. Resist.* 23, 108–110
 49. Fournier, P.-E., Vallenet, D., Barbe, V., Audic, S., Ogata, H., Poirel, L., Richet, H., Robert, C., Mangenot, S., Abergel, C., Nordmann, P., Weissenbach, J., Raoult, D., and Claverie, J.-M. (2006) Comparative Genomics of Multidrug Resistance in *Acinetobacter baumannii*. *PLoS Genet.* 2, e7
 50. Shokryazdan, P., Sieo, C. C., Kalavathy, R., Liang, J. B., Alitheen, N. B., Faseleh Jahromi, M., and Ho, Y. W. (2014) Probiotic Potential of *Lactobacillus* Strains with Antimicrobial Activity against Some Human Pathogenic Strains. *Biomed Res. Int.* 2014, 1–16
 51. Carasi, P., Díaz, M., Racedo, S. M., De Antoni, G., Urdaci, M. C., and Serradell, M. de los A. (2014) Safety Characterization and Antimicrobial Properties of Kefir-Isolated *Lactobacillus kefir*. *Biomed Res. Int.* 2014, 1–7
 52. Pisano, M. B., Viale, S., Conti, S., Fadda, M. E., Deplano, M., Melis, M. P., Deiana, M., and Cosentino, S. (2014) Preliminary Evaluation of Probiotic Properties of *Lactobacillus* Strains Isolated from Sardinian Dairy Products. *Biomed Res. Int.* 2014, 1–9
 53. CLSI (2020) *CLSI M100-ED29: 2021 Performance Standards for Antimicrobial Susceptibility Testing, 30th Edition*

Figures




Figure 1

Inhibitory effect of *Lcb. rhamnosus* CRL 2244 on *A. baumannii* clinical strains. A) Inhibitory activity on *A. baumannii* A118 (AB). The plate of dilution 10⁻⁵ shows the fully inhibited AB lawn, while the plate of dilution 10⁻⁶ shows the inhibition halos around the CRL 2244 colonies. B) Antimicrobial activity of culture (C), pellet (P) and cell supernatant (S) spot of *Lcb. rhamnosus* CRL 2244 on carbapenem-resistant *A. baumannii* strains at 16h incubation.




Figure 2

Killing activity of *Lcb. rhamnosus* CRL 2244 on *A. baumannii* AB5075. A) Cells grew overnight and combined in a 1:1 ratio B) Overnight cultures of both cells in 1:1 ratio with addition of fresh medium. Both conditions were incubated at 37°C for 24 h and CFU/mL were determined at different incubation times for a period of 24 h. All assays were carried out in duplicate.




Figure 3

Scanning electron microscopy of *A. baumannii* cells in the presence of *Lcb. rhamnosus* CRL 2244. *A. baumannii* cells cultures were used as control. Micrographs were captured at a magnification of $\times 10.000$ or $\times 20.000$. Bars, 200 nm.





Figure 4

AB5075 transcriptional results of representative metabolic pathways affected by *Lcb. rhamnosus* CRL 2244. A) Heatmap outlying the differential genes expression of genes involved in the phenylacetic acid catabolic pathway. Asterisks represent a P-value of <0.05. B) qRT-PCR of *paaA*, *paaB*, and *paaE* of AB5075 grew on BHI or in co-culture with *Lcb. rhamnosus* CRL 2244. C) Heatmap outlying the differential genes expression of Hut system codifying genes involved in histidine metabolism. Asterisks represent a

P-value of <0.05. D) qRT-PCR of *hutC*, *hutD*, *hutG*, *hutH*, *hutI*, *hutT*, and *hutU* of AB5057 grew on BHI or in co-culture with *Lcb. rhamnosus* CRL 2244. E) Heatmap representing the differential genes expression genes involved in acetoin metabolism. Asterisks represent a P-value of <0.05. F) qRT-PCR of *acoA*, *acoB*, *acoC*, and *acoR* of AB5057 grew on BHI or in co-culture with *Lcb. rhamnosus* CRL 2244. For qRT-PCR assays three independent samples were used. Statistical significance ($P < 0.05$) was determined by two-way ANOVA followed by Tukey's multiple-comparison test, one asterisks: $P < 0.05$; two asterisks: $P < 0.01$, and three asterisks: $P < 0.001$.

Virulence associated genes



Antibiotic associated genes




Figure 5

Heatmap representing the differential genes expression genes involved in virulence and antibiotic resistance. Asterisks represent a P-value of <0.05 . A) Type 6 secretion systems, B) Biofilm, C) Iron, D) Efflux pumps, and E) antibiotic resistance.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [FigureS1.jpg](#)
- [FigureS2.jpg](#)
- [FigureS3.jpg](#)
- [LegendsofSupplementaryMaterial.docx](#)
- [TableS1.docx](#)
- [TableS2.xlsx](#)